-
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)
Recruiting
More
The primary purpose of this study is to test whether GD2-CAR T cells can be successfully made
from immune cells collected from children and young adults with H3K27M-mutant diffuse
intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG).
H3K27Mmutant testing will occur as part of standard of care prior to enrollment.
Stanford Investigators
View full details
-
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from
dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage
tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more
tumor cells.
PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination
chemotherapy together with radiation therapy works in treating young patients with newly
diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Paul Fisher, 6507258630.
Stanford Investigators
View full details
-
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
Not Recruiting
More
This clinical trial is looking at brain function in young patients receiving methotrexate for
acute lymphoblastic leukemia. Learning about the long-term effects of methotrexate on brain
function may help doctors plan cancer treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
Not Recruiting
More
The purpose of this study is to examine the safety and efficacy of XERECEPT (human
Corticotropin-Releasing Factor, or hCRF) compared to dexamethasone in patients with primary
malignant glioma who require increased dexamethasone doses to control symptom of peritumoral
brain edema.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cathy Recht, 6507258630.
Stanford Investigators
View full details
-
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
Not Recruiting
More
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone
(Decadron) a common treatment for symptoms of brain swelling (edema). This study is
specifically aimed at patients who require chronic high doses of dexamethasone to manage
symptoms.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lynn Adler, 6507258630.
Stanford Investigators
View full details
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
Not Recruiting
More
RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat
brain tumors in young children. Using chemotherapy gives the brain more time to develop
before radiation is given. The chemotherapy in this study includes the drug methotrexate.
This drug was an important part of the two clinical trials which resulted in the best
survival results for children less than 3 years of age with medulloblastoma. Most patients
treated on this trial will also receive radiation which is carefully targeted to the area of
the tumor. This type of radiation (focal conformal or proton beam radiotherapy) may result in
fewer problems with thinking and learning than radiation to the whole brain and spinal cord.
PURPOSE: This clinical trial is studying how well giving combination chemotherapy together
with radiation therapy works in treating young patients with newly diagnosed central nervous
system tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma
Not Recruiting
More
To investigate the safety of delivering arsenic trioxide (ATO) in combination with
stereotactic radiotherapy in recurrent malignant glioma by performing an open label, Phase I
dose escalation trial. Results from this study will provide a basis for further study of ATO
combined with radiation therapy as a radiosensitizer for malignant brain tumors in future
Phase II studies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laurie Tupper, 6504984143.
Lead Sponsor
Stanford Investigators
View full details
-
Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment
Not Recruiting
More
The purpose of this study is to evaluate the efficacy, safety and tolerability of donepezil
in children with persistent attention impairment that is present at least 12 months after the
completion of cancer treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
Not Recruiting
More
This phase II trial studies how well vismodegib works in treating younger patients with
recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Prianka Kumar, 650-724-3866.
Stanford Investigators
View full details
-
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Not Recruiting
More
Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205
and either progressed while on study or discontinued due to unacceptable toxicity related to
etoposide were allowed to participate in this study to assess the safety profile of
single-agent erlotinib in participants with recurrent or refractory pediatric ependymoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Carissa Bailey, 6507254708.
Stanford Investigators
View full details
-
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Not Recruiting
More
This phase I trial studies the side effects and best dose of pomalidomide in treating younger
patients with tumors of the brain or spine (central nervous system) that have come back or
are continuing to grow. Pomalidomide may interfere with the ability of tumor cells to grow
and spread and may also stimulate the immune system to kill tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Stanford Investigators
View full details
-
Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery
Not Recruiting
More
This phase II trial studies how well peginterferon alfa-2b works in treating younger patients
with craniopharyngioma that is recurrent or cannot be removed by surgery. Peginterferon
alfa-2b may interfere with the growth of tumor cells and slow the growth of
craniopharyngioma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Not Recruiting
More
This phase I trial studies the side effects and best dose of panobinostat in treating younger
patients with diffuse intrinsic pontine glioma (DIPG). Panobinostat may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Stratum 1 treats patients
with DIPG that has returned or gotten worse (progressed). Stratum 2 treats patients with DIPG
or H3K27+Thalamic Diffuse Malignant Glioma (DMG) that has not yet gotten worse.
Currently, only Stratum 2 is enrolling patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to
stop tumor cells from dividing so they stop growing or die. Radiation therapy uses
high-energy x-rays to damage tumor cells and may be an effective treatment for patients with
glioma. Drugs such as arsenic trioxide may also make the tumor cells more sensitive to
radiation therapy. Combining arsenic trioxide with radiation therapy may kill more tumor
cells.
PURPOSE: Phase I trial to study the effectiveness of combining arsenic trioxide with
radiation therapy in treating patients who have newly diagnosed gliomas.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
FLT-PET Imaging of Brain Tumors in Children
Not Recruiting
More
Brain tumors are the leading cause of death from solid tumors in children. Tumor imaging is
important in the management of these tumors, but current imaging methods have limitations in
providing the necessary information for optimal treatment of these patients. The goal of this
study is to evaluate the potential utility of positron emission tomography (PET) with
3'-deoxy-3'-[F-18] fluorothymidine (18F-FLT) in the medical management of brain tumors in
children. Funding source - FDA Office of Orphan Product Development (OOPD)
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Not Recruiting
More
This molecular biology and phase II trial studies how well imetelstat sodium works in
treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-736-4281.
Stanford Investigators
View full details
-
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Not Recruiting
More
This phase I/II trial studies the side effects and the best dose of veliparib when given
together with radiation therapy and temozolomide and to see how well they work in treating
younger patients newly diagnosed with diffuse pontine gliomas. Veliparib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses
high-energy x rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide,
work in different ways to stop the growth of tumor cells either by killing the cells or by
stopping them from dividing. Giving veliparib with radiation therapy and temozolomide may
kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-736-4281.
Stanford Investigators
View full details
-
Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy
Not Recruiting
More
RATIONALE: Methylphenidate hydrochloride or modafinil may help reduce daytime sleepiness and
improve the quality of life of patients with excessive daytime sleepiness after cancer
therapy. It is not yet known whether methylphenidate hydrochloride or modafinil are more
effective than a placebo in reducing daytime sleepiness in these patients.
PURPOSE: This randomized phase II trial is studying methylphenidate hydrochloride or
modafinil to see how well they work compared with a placebo in treating young patients with
excessive daytime sleepiness after cancer therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Not Recruiting
More
This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral
etoposide in patients with recurrent or refractory pediatric ependymoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Carissa Bailey, 6507254708.
Stanford Investigators
View full details
-
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Not Recruiting
More
This multi-institutional study will prospectively collect tumor and constitutional tissue
samples from patients with diffuse brainstem glioma and other types of brainstem gliomas
either during therapy or at autopsy to perform an extensive analysis of genetic and molecular
abnormalities in these tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Monje, .
Stanford Investigators
View full details
-
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Not Recruiting
More
This phase I trial studies the side effects and best dose of palbociclib isethionate in
treating younger patients with central nervous system tumors that have grown, come back, or
not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Prianka Kumar, 650-724-3866.
Stanford Investigators
View full details
-
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Not Recruiting
More
This phase II trial studies how well chemotherapy followed by radiation therapy work in
treating younger patients with newly diagnosed central nervous system germ cell tumors that
have not spread to other parts of the brain, spinal canal, or body (localized). Drugs used as
chemotherapy, such as carboplatin, etoposide, and ifosfamide, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Radiation therapy uses high-energy x rays to kill tumor cells.
Giving chemotherapy followed by radiation therapy may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-497-8953.
Stanford Investigators
View full details
-
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
Not Recruiting
More
The purpose of this study is to examine the long-term safety and tolerability of human
corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone
(Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to
all patients who participate in either of the blinded studies, NTI 0302, NTI 0303, or other
designated studies, including patients who may have discontinued blinded study medication
early but completed the protocol-stipulated follow-up periods.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lynn Adler, 6507258630.
Stanford Investigators
View full details
-
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Not Recruiting
More
The goal of this clinical research study is to learn if the combination of Avastin
(bevacizumab) and Tykerb (lapatinib) can help to control ependymoma in pediatric patients.
The safety of this drug combination will also be studied.
Stanford is currently not accepting patients for this trial.
For more information, please contact Carissa Bailey, 6507254708.
Stanford Investigators
View full details
-
Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
Not Recruiting
More
This is a research study of patients with diffuse intrinsic pontine gliomas. We hope to learn
about the safety and efficacy of treating pediatric diffuse intrinsic pontine glioma patients
with the EGFRvIII peptide vaccine after conventional radiation.
Stanford is currently not accepting patients for this trial.
For more information, please contact Christina Huang, 650-723-0574.
Stanford Investigators
View full details
-
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
Recruiting
More
This phase I trial studies the side effects and best dose of pembrolizumab and to see how
well it works in treating younger patients with high-grade gliomas (brain tumors that are
generally expected to be fast growing and aggressive), diffuse intrinsic pontine gliomas
(brain stem tumors), brain tumors with a high number of genetic mutations, ependymoma or
medulloblastoma that have come back (recurrent), progressed, or have not responded to
previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may induce changes in the body's immune system, and may interfere with the
ability of tumor cells to grow and spread.
Stanford Investigators
View full details
-
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Not Recruiting
More
This phase I/II trial studies the side effects and the best dose of selumetinib and how well
it works in treating or re-treating young patients with low grade glioma that has come back
(recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Prianka Kumar, 650-724-3866.
Stanford Investigators
View full details
-
Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Not Recruiting
More
This feasibility trial studies how well the Optune device works in treating younger patients
with recurrent/refractory/progressive supratentorial malignant glioma and ependymoma. The
TTFields generated by Optune device may inhibit the growth of tumor.
Stanford is currently not accepting patients for this trial.
For more information, please contact Paul G. Fisher, MD, MHS, 650-497-8953.
Stanford Investigators
View full details